[go: up one dir, main page]

CL2019002172A1 - Agente terapéutico para enfermedades del hígado. - Google Patents

Agente terapéutico para enfermedades del hígado.

Info

Publication number
CL2019002172A1
CL2019002172A1 CL2019002172A CL2019002172A CL2019002172A1 CL 2019002172 A1 CL2019002172 A1 CL 2019002172A1 CL 2019002172 A CL2019002172 A CL 2019002172A CL 2019002172 A CL2019002172 A CL 2019002172A CL 2019002172 A1 CL2019002172 A1 CL 2019002172A1
Authority
CL
Chile
Prior art keywords
liver
therapeutic agent
liver diseases
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
CL2019002172A
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Yun Soo Bae
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CL2019002172A1 publication Critical patent/CL2019002172A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DIVULGA UNA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR LA ENFERMEDAD DE HÍGADO GRASO, COMPOSICIÓN QUE CONTIENE, COMO UN INGREDIENTE ACTIVO, UN COMPUESTO A BASE DE PIRAZOL O SU SAL FARMACÉUTICAMENTE ACEPTABLE. EL 3-FENIL4-ALQUIL-L-(PIRIDIN-2-IL)-LH-PIRAZOL-5-OL O SU SAL FARMACÉUTICAMENTE ACEPTABLE ESTÁ EN CAPACIDAD DE INHIBIR EFECTIVAMENTE EL HÍGADO GRASO, LA INFLAMACIÓN HEPÁTICA Y LA FIBROSIS HEPÁTICA, Y ES ÚTIL PARA PREVENIR O TRATAR NAFLD, EN PARTICULAR, NASH.
CL2019002172A 2017-11-01 2019-08-01 Agente terapéutico para enfermedades del hígado. CL2019002172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170144911A KR101840702B1 (ko) 2017-11-01 2017-11-01 간질환 치료제

Publications (1)

Publication Number Publication Date
CL2019002172A1 true CL2019002172A1 (es) 2019-10-25

Family

ID=61901100

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002172A CL2019002172A1 (es) 2017-11-01 2019-08-01 Agente terapéutico para enfermedades del hígado.

Country Status (15)

Country Link
US (1) US10966969B2 (es)
EP (1) EP3573617B1 (es)
JP (1) JP6812564B2 (es)
KR (1) KR101840702B1 (es)
CN (1) CN110248659B (es)
AU (1) AU2018358496B2 (es)
BR (1) BR112019015715A2 (es)
CA (1) CA3050865C (es)
CL (1) CL2019002172A1 (es)
CO (1) CO2019008053A2 (es)
ES (1) ES2984413T3 (es)
MX (1) MX386033B (es)
PL (1) PL3573617T3 (es)
RU (1) RU2723686C1 (es)
WO (1) WO2019088444A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
EP4134079A4 (en) * 2020-04-08 2024-04-24 Aptabio Therapeutics Inc. AGENT FOR THE TREATMENT OF ACUTE KIDNEY INJURY INDUCED BY CONTRAST PRODUCT
CN115427039B (zh) * 2020-04-13 2025-04-04 阿普塔生物治疗公司 包含吡唑衍生物的肺纤维化药物
KR102386097B1 (ko) * 2020-04-13 2022-04-14 압타바이오 주식회사 피라졸 유도체의 폐섬유증 치료제
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007210978A (ja) 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
ATE550334T1 (de) 2006-09-01 2012-04-15 Otsuka Agritechno Co Ltd N-pyridylpiperidinverbindung, verfahren zu ihrer herstellung und schädlingsbekämpfungsmittel
KR100942382B1 (ko) 2008-03-25 2010-02-12 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A2 (ko) * 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
RS56669B1 (sr) 2009-12-21 2018-03-30 Samumed Llc 1h-pirazolo[3,4-b]piridini i njihove terapeutske primene
JP2013249256A (ja) 2010-09-15 2013-12-12 Astellas Pharma Inc 脂肪性肝疾患治療薬
KR20120098489A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR20120098462A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
US8962845B2 (en) 2011-09-30 2015-02-24 National Health Research Institutes Pyrazole compounds
KR101633957B1 (ko) * 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
US9695127B2 (en) 2012-11-08 2017-07-04 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating HIV and methods for using the compounds
CN104288149B (zh) 2014-10-22 2017-02-15 山东大学 4‑氯‑2‑(5‑苯基‑1‑(吡啶‑2‑基)‑4,5‑二氢‑1h‑吡唑‑3‑基)苯酚在制药中的应用
JP2019077615A (ja) 2016-03-09 2019-05-23 公立大学法人和歌山県立医科大学 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤
KR101856444B1 (ko) * 2017-04-20 2018-05-10 압타바이오 주식회사 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
KR101840702B1 (ko) 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제

Also Published As

Publication number Publication date
JP2020506917A (ja) 2020-03-05
CA3050865A1 (en) 2019-05-09
AU2018358496A1 (en) 2019-08-08
KR101840702B1 (ko) 2018-03-22
CA3050865C (en) 2022-07-12
AU2018358496B2 (en) 2020-12-10
ES2984413T3 (es) 2024-10-29
EP3573617A1 (en) 2019-12-04
BR112019015715A2 (pt) 2020-03-24
MX386033B (es) 2025-03-18
EP3573617A4 (en) 2020-04-22
CN110248659A (zh) 2019-09-17
CO2019008053A2 (es) 2019-10-21
PL3573617T3 (pl) 2024-07-15
RU2723686C1 (ru) 2020-06-17
US10966969B2 (en) 2021-04-06
JP6812564B2 (ja) 2021-01-13
WO2019088444A1 (en) 2019-05-09
MX2019008870A (es) 2020-01-20
CN110248659B (zh) 2022-08-19
US20200390752A1 (en) 2020-12-17
EP3573617B1 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
CL2020000747A1 (es) Formulaciones de niraparib.
CO2018001375A2 (es) Composiciones de retinoides tópicos
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2017016774A (es) Agente terapeutico para la fibrosis.
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
CR20160021A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
NI201200196A (es) Agentes terapéuticos 976